MiRNA-520b and MiR-520e Sensitize Breast Cancer Cells to Complement Attack Via Directly Targeting 3'UTR of CD46
Overview
Pharmacology
Authors
Affiliations
MicroRNAs (miRNAs), non-coding RNAs that function as post-transcriptional gene regulators, play a pivotal role in cancer development. In the present study, we elucidated the roles of miR-520b and miR-520e in breast cancer cells. We examined the expression levels of miR-520b and miR-520e in the immortalized breast cell line, HBL-100, and in three breast cancer cell lines: MCF-7, LM-MCF-7 and MDA-MB-231. We show the expression levels of miR-520b and miR-520e in the breast cancer cell lines were lower than that in the HBL-100 cells. Furthermore, the breast cancer cell lines showed less sensitivity to complement-dependent cytotoxicity (CDC). We found that overexpression of miR-520b and miR-520e increases the sensitivity of the breast cancer cells to CDC, whereas further suppression of miR-520b and miR-520e decreases the sensitivity of the breast cancer cells to CDC. We then demonstrate that miR-520b and miR-520e are able to directly target the 3'untranslated regions (3'UTR) of the membrane-bound complement regulatory protein CD46; suggesting that miR-520b and miR-520e down-regulate CD46 at post-transcriptional level. Enzyme-linked immunosorbent assay (ELISA) showed that overexpression of miR-520b and miR-520e results in the increased expression of C3b, which is mediated by downregulated CD46. These results suggest that miRNA-520b and miR-520e mediated down-regulation of CD46 induces opsonization of cancer cells via an alternative pathway resulting in complement activation. Thus, we conclude that miR-520b and miR-520e contribute to CDC in breast cancer cells via directly targeting the 3'UTR of CD46.
Altalebi S, Haghi M, Feizi M Mol Biol Rep. 2023; 50(12):9825-9831.
PMID: 37840066 DOI: 10.1007/s11033-023-08801-x.
Zhu Z, Jiang L, Ding X Cancers (Basel). 2023; 15(16).
PMID: 37627192 PMC: 10452610. DOI: 10.3390/cancers15164164.
Papadakos S, Stergiou I, Gkolemi N, Arvanitakis K, Theocharis S Cancers (Basel). 2023; 15(13).
PMID: 37444544 PMC: 10340246. DOI: 10.3390/cancers15133434.
Dai Y, Liu J, Li X, Deng J, Zeng C, Lu W Cancer Sci. 2022; 114(5):1882-1897.
PMID: 36445120 PMC: 10154867. DOI: 10.1111/cas.15678.
Mortazavi-Jahromi S, Aslani M Int Immunopharmacol. 2022; 110:109040.
PMID: 35839566 PMC: 9271492. DOI: 10.1016/j.intimp.2022.109040.